Article

Exome Sequencing Identifies Mutations in CCDC114 as a Cause of Primary Ciliary Dyskinesia.

Department of Medicine, UNC School of Medicine, Chapel Hill, NC 27599, USA. Electronic address: .
The American Journal of Human Genetics (Impact Factor: 10.99). 12/2012; DOI: 10.1016/j.ajhg.2012.11.003
Source: PubMed

ABSTRACT Primary ciliary dyskinesia (PCD) is a genetically heterogeneous, autosomal-recessive disorder, characterized by oto-sino-pulmonary disease and situs abnormalities. PCD-causing mutations have been identified in 14 genes, but they collectively account for only ∼60% of all PCD. To identify mutations that cause PCD, we performed exome sequencing on six unrelated probands with ciliary outer dynein arm (ODA) defects. Mutations in CCDC114, an ortholog of the Chlamydomonas reinhardtii motility gene DCC2, were identified in a family with two affected siblings. Sanger sequencing of 67 additional individuals with PCD with ODA defects from 58 families revealed CCDC114 mutations in 4 individuals in 3 families. All 6 individuals with CCDC114 mutations had characteristic oto-sino-pulmonary disease, but none had situs abnormalities. In the remaining 5 individuals with PCD who underwent exome sequencing, we identified mutations in two genes (DNAI2, DNAH5) known to cause PCD, including an Ashkenazi Jewish founder mutation in DNAI2. These results revealed that mutations in CCDC114 are a cause of ciliary dysmotility and PCD and further demonstrate the utility of exome sequencing to identify genetic causes in heterogeneous recessive disorders.

0 Followers
 · 
118 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary ciliary dyskinesia (PCD) is a genetically heterogeneous disorder caused by cilia and sperm dysmotility. About 12% of cases show perturbed 9+2 microtubule cilia structure and inner dynein arm (IDA) loss, historically termed 'radial spoke defect'. We sequenced CCDC39 and CCDC40 in 54 'radial spoke defect' families, as these are the two genes identified so far to cause this defect. We discovered biallelic mutations in a remarkable 69% (37/54) of families, including identification of 25 (19 novel) mutant alleles (12 in CCDC39 and 13 in CCDC40). All the mutations were nonsense, splice and frameshift predicting early protein truncation, which suggests this defect is caused by 'null' alleles conferring complete protein loss. Most families (73%; 27/37) had homozygous mutations, including families from outbred populations. A major putative hotspot mutation was identified, CCDC40 c.248delC, as well as several other possible hotspot mutations. Together, these findings highlight the key role of CCDC39 and CCDC40 in PCD with axonemal disorganisation and IDA loss, and these genes represent major candidates for genetic testing in families affected by this ciliary phenotype. We show that radial spoke structures are largely intact in these patients and propose this ciliary ultrastructural abnormality be referred to as 'IDA and nexin-dynein regulatory complex (N-DRC) defect', rather than 'radial spoke defect'.
    Human Mutation 12/2012; DOI:10.1002/humu.22261 · 5.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die primäre ziliäre Dyskinesie (PCD) ist eine seltene angeborene Erkrankung der Zilien, die sich zumeist im respiratorischen System manifestiert.Bei klinischem Verdacht auf das Vorliegen einer PCD und/oder bei positivem Screening (erniedrigte nasale NO-Werte) sollten Patienten zeitnah weitere diagnostische Maßnahmen durchlaufen. In Zentren, in denen eine Hochfrequenzvideomikroskopieanalyse (HVMA) des Zilienschlags zur Verfügung steht, ist eine initiale nasale NO-Messung zum Screening nicht zwingend erforderlich. Als erste diagnostische Maßnahme zur Sicherung oder zum Ausschluss einer PCD sollte eine HVMA erfolgen. Bei auffälligem Befund sind eine transmissionselektronenmikroskopische Analyse (TEM) der Ultrastruktur und eine hochauflösende immunfluoreszenzmikroskopische Analyse (IF) der Zilien anzuschließen. Obligat für die Diagnosestellung sind mindestens 2 kongruente pathologische Befunde aus HVMA, TEM oder IF. Wenn eine PCD-Variante ohne Hinweis auf einen ultrastrukturellen Defekt vorliegt, muss ein identischer pathologischer Zilienschlag mittels HVMA an insgesamt 3 unabhängigen Terminen belegt werden. Danach sollte auf Basis der erhobenen Befunde für HVMA, TEM und IF eine gerichtete genetische Abklärung angestrebt werden. Ein eindeutiger genetischer Befund kann die Diagnose ebenfalls sichern. Bei Verdacht auf eine PCD soll Kontakt mit einem Diagnosezentrum aufgenommen werden. Ein Referenzzentrum für PCD-Diagnostik evaluiert unklare Befunde.
    Monatsschrift Kinderheilkunde 05/2013; 161(5). DOI:10.1007/s00112-012-2798-y · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive disorder of motile cilia that leads to oto-sino-pulmonary diseases and organ laterality defects in ~50% of cases. The estimated incidence of PCD is ~1 per 15,000 births, but the prevalence of PCD is difficult to determine, primarily because of limitations in diagnostic methods that focus on testing ciliary ultrastructure and function. Diagnostic capabilities have recently benefitted from 1) documentation of low nasal nitric oxide (nNO) production in PCD, and 2) discovery of biallelic mutations in multiple PCD-causing genes. The use of these complementary diagnostic approaches shows that at least 30% of PCD patients have normal ciliary ultrastructure. More accurate identification of PCD patients has also allowed definition of a strong clinical phenotype, which includes neonatal respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth, and early development of recurrent/chronic middle-ear and sinus disease. Recent studies, using advanced imaging and pulmonary physiologic assessments, clearly demonstrate early onset of lung disease in PCD, with abnormal air flow mechanics by age 6-8 years that is similar to cystic fibrosis, and age-dependent onset of bronchiectasis. The treatment of PCD is not standardized, and there are no validated PCD-specific therapies. Most PCD patients receive sub-optimal management, which should include airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use of antibiotics targeted to pathogens. The PCD Foundation is developing a network of clinical centers, which should improve diagnosis and management of PCD.
    American Journal of Respiratory and Critical Care Medicine 06/2013; DOI:10.1164/rccm.201301-0059CI · 11.99 Impact Factor